Laura Despierres1, Abdou Beziane1, Gilles Kaplanski1, Brigitte Granel1, Jacques Serratrice1, William Cohen2, Florence Bretelle1, Pascal Rossi1, Pierre-Emmanuel Morange2, Pierre Jean Weiller1, Jean Robert Harlé1, Pierre Bongrand1, Nathalie Bardin3. 1. Laboratoire d'Immunologie, Service de Médecine Interne, Hôpital de la Conception, Service de Médecine Interne, Hôpital Nord, Service de Médecine Interne, Laboratoire d'Hématologie, Hôpital de la Timone, Laboratoire d'Adhésion et d'Inflammation, Université Aix-Marseille, Service de Gynécologie obstétrique, Hôpital Nord and Laboratoire d'Immunologie, UFR Pharmacie, Université Aix-Marseille, UMRS1076, Marseille, France. 2. Laboratoire d'Immunologie, Service de Médecine Interne, Hôpital de la Conception, Service de Médecine Interne, Hôpital Nord, Service de Médecine Interne, Laboratoire d'Hématologie, Hôpital de la Timone, Laboratoire d'Adhésion et d'Inflammation, Université Aix-Marseille, Service de Gynécologie obstétrique, Hôpital Nord and Laboratoire d'Immunologie, UFR Pharmacie, Université Aix-Marseille, UMRS1076, Marseille, France.Laboratoire d'Immunologie, Service de Médecine Interne, Hôpital de la Conception, Service de Médecine Interne, Hôpital Nord, Service de Médecine Interne, Laboratoire d'Hématologie, Hôpital de la Timone, Laboratoire d'Adhésion et d'Inflammation, Université Aix-Marseille, Service de Gynécologie obstétrique, Hôpital Nord and Laboratoire d'Immunologie, UFR Pharmacie, Université Aix-Marseille, UMRS1076, Marseille, France. 3. Laboratoire d'Immunologie, Service de Médecine Interne, Hôpital de la Conception, Service de Médecine Interne, Hôpital Nord, Service de Médecine Interne, Laboratoire d'Hématologie, Hôpital de la Timone, Laboratoire d'Adhésion et d'Inflammation, Université Aix-Marseille, Service de Gynécologie obstétrique, Hôpital Nord and Laboratoire d'Immunologie, UFR Pharmacie, Université Aix-Marseille, UMRS1076, Marseille, France.Laboratoire d'Immunologie, Service de Médecine Interne, Hôpital de la Conception, Service de Médecine Interne, Hôpital Nord, Service de Médecine Interne, Laboratoire d'Hématologie, Hôpital de la Timone, Laboratoire d'Adhésion et d'Inflammation, Université Aix-Marseille, Service de Gynécologie obstétrique, Hôpital Nord and Laboratoire d'Immunologie, UFR Pharmacie, Université Aix-Marseille, UMRS1076, Marseille, France. nathalie.bardin@ap-hm.fr.
Abstract
OBJECTIVES: Although the last international guidelines for aPL recommended determination of IgA aCL and anti-β2glycoprotein I (aβ2GPI) antibodies for the evaluation of APS in the absence of conventional IgG or IgM aCL and aβ2GPI antibodies, the clinical value of these antibodies remains controversial. We evaluated the clinical utility of IgA aPL and of the determination of target domains of aβ2GPI IgA antibodies. METHODS: A retrospective analysis was performed on sera from 439 patients referred for routine detection of aPL IgA by in-house ELISA. Sera positive for aβ2GPI IgA were subsequently tested for aβ2GPI domain 1 (D1) and domain 4/5 (D4/5) antibodies using ELISAs. RESULTS: The prevalence of aβ2GPI IgA antibodies was 16% in patients, significantly different from controls (1%, P < 0.0001). These antibodies were associated with clinical contexts related to APS as thrombosis (28.6% vs. 15%, P = 0.009) and SLE (42% vs. 15%, P < 0.0001). Interestingly, determination of their target domains revealed a significant association between aβ2GPI IgA directed against D4/5 and SLE without thrombosis (66.7 vs. 16.7%, P = 0.002). In contrast, aCL IgA were not more prevalent in patients than in controls. CONCLUSION: Our study confirmed the interest of aβ2GP1 IgA in the exploration of APS and suggests that identification of target domains of aβ2GP1 IgA may be useful in the evaluation of thrombotic risk in SLE patients.
OBJECTIVES: Although the last international guidelines for aPL recommended determination of IgA aCL and anti-β2glycoprotein I (aβ2GPI) antibodies for the evaluation of APS in the absence of conventional IgG or IgM aCL and aβ2GPI antibodies, the clinical value of these antibodies remains controversial. We evaluated the clinical utility of IgA aPL and of the determination of target domains of aβ2GPI IgA antibodies. METHODS: A retrospective analysis was performed on sera from 439 patients referred for routine detection of aPL IgA by in-house ELISA. Sera positive for aβ2GPI IgA were subsequently tested for aβ2GPI domain 1 (D1) and domain 4/5 (D4/5) antibodies using ELISAs. RESULTS: The prevalence of aβ2GPI IgA antibodies was 16% in patients, significantly different from controls (1%, P < 0.0001). These antibodies were associated with clinical contexts related to APS as thrombosis (28.6% vs. 15%, P = 0.009) and SLE (42% vs. 15%, P < 0.0001). Interestingly, determination of their target domains revealed a significant association between aβ2GPI IgA directed against D4/5 and SLE without thrombosis (66.7 vs. 16.7%, P = 0.002). In contrast, aCL IgA were not more prevalent in patients than in controls. CONCLUSION: Our study confirmed the interest of aβ2GP1 IgA in the exploration of APS and suggests that identification of target domains of aβ2GP1 IgA may be useful in the evaluation of thrombotic risk in SLEpatients.
Authors: M Frodlund; A Vikerfors; G Grosso; T Skogh; J Wetterö; K Elvin; I Gunnarsson; A Kastbom; Ö Dahlström; J Rönnelid; E Svenungsson; C Sjöwall Journal: Clin Exp Immunol Date: 2018-09-12 Impact factor: 4.330
Authors: Ellen De Langhe; Xavier Bossuyt; Long Shen; Kishore Malyavantham; Julian L Ambrus; Lakshmanan Suresh Journal: Open Rheumatol J Date: 2017-01-31
Authors: S Elbagir; N A Mohammed; H Kaihola; E Svenungsson; I Gunnarsson; V A Manivel; E Pertsinidou; E M Elagib; M A M Nur; E A Elussein; A Elshafie; H Åkerud; J Rönnelid Journal: Lupus Date: 2020-02-27 Impact factor: 2.911
Authors: Carlos Tortosa; Oscar Cabrera-Marante; Manuel Serrano; José A Martínez-Flores; Dolores Pérez; David Lora; Luis Morillas; Estela Paz-Artal; José M Morales; Daniel Pleguezuelo; Antonio Serrano Journal: PLoS One Date: 2017-07-20 Impact factor: 3.240
Authors: Sahwa Elbagir; Amir I Elshafie; Elnour M Elagib; NasrEldeen A Mohammed; Mawahib Ie Aledrissy; Vivek Anand Manivel; Eleftheria Pertsinidou; Musa Am Nur; Iva Gunnarsson; Elisabet Svenungsson; Johan Rönnelid Journal: Lupus Date: 2020-08-02 Impact factor: 2.911